Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497356 | 0.86 | HRH3 (0.56) | HRH3KCNH2KDM4ECYP3A4CYP2C9 | |
| SCHEMBL497233 | 0.85 | HRH3 (0.43) | HRH3KCNH2KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3371664 | 0.78 | NAAA (0.47) | HRH3KCNH2KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3372267 | 0.78 | NAAA (0.47) | HRH3KCNH2KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL28035300 | 0.75 | ITGA4 (0.47) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL4670410 | 0.75 | HRH3 (0.73) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL25319515 | 0.74 | AKR1C3 (0.42) | HRH3KDM4ESMN1; SMN2ALDH1A1CYP2C9 | |
| SCHEMBL27875627 | 0.74 | USP30 (0.44) | ALDH1A1 | |
| SCHEMBL3790233 | 0.74 | USP30 (0.44) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL497091 | 0.74 | HRH3 (0.67) | HRH3KCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-2266979-A1 | 2-morpholino-4-pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1789414-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | HRH3 2173/4885KCNH2 901/4885KDM4E 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.